|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 1208-1216
Bcl-2 and Bcl-XL Can Differentially Block Chemotherapy-Induced Cell Death
By
Philip L. Simonian,
Didier A.M. Grillot, and
Gabriel Nuñez
From the Department of Pathology and Comprehensive Cancer Center, The University of Michigan Medical School, Ann Arbor, MI.
 |
ABSTRACT |
Bcl-2 and its homologue Bcl-XL are expressed in a variety of tumors and their expression modulates the sensitivity of tumor cells to a wide spectrum of chemotherapeutic agents and  -irradiation. In the present report, we generated clones of FL5.12 lymphoid cells with similar levels of Bcl-2 and Bcl-XL using the Flag epitope to determine if these survival proteins could provide equivalent protection when challenged with chemotherapy or -irradiation. Using four M-phase specific chemotherapeutic agents, Bcl-XL and Bcl-2 provided similar protection against vincristine and vinblastine whereas Bcl-XL afforded as much as 50% greater cell viability than Bcl-2 against etoposide and teniposide-induced cell death. In addition, Bcl-XL provided significantly greater cell viability than Bcl-2 against methotrexate, fluorouracil, and hydroxyurea, three S-phase specific agents. In apoptosis induced by -irradiation and cisplatin, two antitumor treatments that are cell-cycle phase-nonspecific agents, both Bcl-XL and Bcl-2 conferred similar protection against -irradiation, but Bcl-XL provided better protection than Bcl-2 against cisplatin. These results indicate that Bcl-XL and Bcl-2 confer a differential ability to protect against chemotherapy-induced cell death, which appears to be dependent on the molecular mechanism targeted by the drug rather than its cell-cycle phase specificity.
| |
INTRODUCTION |
APOPTOSIS, a morphologically distinguished type of programmed cell death, is critical not only during development but also in the pathogenesis of a variety of diseases including cancer, autoimmune disease, viral infection, and neurodegenerative disorders.1 The bcl-2 gene, the first member of a rapidly expanding family of genes that regulate apoptosis, was initially isolated from the t(14; 18) chromosomal translocation found in human B-cell lymphomas.2 Subsequently, Bcl-2 has been shown to repress cell death triggered by a diverse array of stimuli including chemotherapy and -irradiation.3 Relatively high levels of Bcl-2 protein have been detected in 20% of patients with acute myelogenous leukemia and in 70% with chronic lymphocytic leukemia.4,5 Moreover, immunohistochemical analysis of the Bcl-2 protein has indicated that alterations in either the levels or patterns of Bcl-2 expression, or both, can occur in a variety of solid tumors.6 Bcl-XL a functional and structural homologue of Bcl-2, also provides protection against a wide variety of chemotherapeutic agents.7 Interestingly, expression levels of the Bcl-2 family of proteins change as tumors become more malignant or after treatment suggesting that expression of these survival proteins is critical not only for tumor development, but also for tumor progression and resistance to therapy.8,9 The mechanism by which Bcl-2 and Bcl-XL provide chemotherapy resistance is unknown, but it is thought that these survival proteins act at a common final step in the cell death pathway induced by antitumor agents.9,10
Initial studies suggested that Bcl-XL protected better than Bcl-2 against apoptosis induced by the immunosuppressant drugs cyclosporin A, FK-506, and rapamycin.11 However, these studies were inconclusive in that levels of Bcl-2 and Bcl-XL could not be directly compared as they were determined using different antibodies. In the present studies, we transfected FL5.12 lymphoid cells with expression constructs that produce Flag-epitope tagged Bcl-2 and Bcl-XL and developed cell clones that express similar levels of these proteins as determined with a Flag-specific antibody. Our results show that Bcl-XL protected significantly better than Bcl-2 against cell death induced by several chemotherapy agents. However, the differential ability of Bcl-XL and Bcl-2 against chemotherapy-induced apoptosis was not universal and appeared to be dependent on the molecular mechanism or cellular target of the drug rather than its cell-cycle phase specificity. The implications of these findings for tumor therapy and chemotherapy-resistance are discussed.
| |
MATERIALS AND METHODS |
Cell culture and transfection.
FL5.12 cells were cultured in interleukin-3 (IL-3) conditioned medium as described.12 FL5.12 were transfected by electroporation (200 V, 960 mF ) with 10 mg of the pSFFV-Neo plasmid containing either Flag-bcl-XL or Flag-bcl-2 in the sense orientation or control pSFFV-Neo plasmid as previously described.13 Individual cell clones were selected for growth in the presence of G418 (1.0 mg/mL) by limiting dilution. Similar levels of protein expression for Flag-Bcl-XL and Flag-Bcl-2 in single cell clones was analyzed by flow cytometry using anti-Flag monoclonal antibody (MoAb) (M2) (Scientific Imaging Systems, Rochester, NY) as described13 and confirmed by immunoblot analysis as described below. Multiple clones expressing similar levels of Flag-Bcl-XL and Flag-Bcl-2 were randomly selected for further study.
Immunoblot analysis.
The expression of Flag-Bcl-XL and Flag-Bcl-2 was determined by immunoblot analysis as previously described.14 Briefly, 1 × 106 cells were lysed in NP-40 isotonic lysis buffer with freshly added protease inhibitors and electrophoresed through 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gels, transferred to nitrocellulose, blocked with 5% nonfat dry milk (Nestle Food Co, Glendale, CA) and incubated with anti-Flag MoAb (1 mg/mL). Equal protein loading was assessed by immunoblotting with anti- -tubulin Ab (clone TUB 2.1) (Sigma Chemicals, St Louis, MO) as described.15 The reaction was developed by enhanced chemiluminescence using the ECL kit (Amersham, Arlington Heights, IL) after incubation with horseradish peroxidase-conjugated goat antimouse secondary antibody (Jackson Laboratories, Inc, West Grove, PA) and exposed to film for 1 minute (Kodak, Rochester, NY) as described.14 For immunoblot analysis of endogenous expression of Bcl-XL, Bcl-2, Bax, and Bad at 24 hours of incubation in each chemotherapy drug, FL5.12 control cells (Neo) were lysed as above and 50 mg of total protein separated and transferred to a nitrocellulose membrane as above and incubated in anti-Bcl-X MoAb (1:2,000), hamster antimouse Bcl-2 MoAb (clone 3F11) (Pharmingen, San Diego, CA), rabbit polyclonal anti-Bax (1:1,000) (a gift of Dr Leber, McMaster University, Hamilton, Ontario) or rabbit polyclonal anti-Bad (N 20) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) and the blots developed as above. Control FL5.12 (Neo) cells were seeded (1 × 105 cells/mL) in each chemotherapy drug at concentrations indicated in the figure legends for time-course experiments (10 µg/mL of fluorouracil, hydroxyurea, or cisplatin) and harvested for immunoblot analysis as described above.
Chemotherapy and radiation-induced cell death assays.
Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and either vincristine (Eli Lilly and Co, Indianapolis, IN), vinblastine (Bedford Laboratories, Bedford, OH), etoposide (Gensia Laboratories, LTD, Irvine, CA), teniposide (Bristol Laboratories, Princeton, NJ), methotrexate (Lederle Parenterals, Inc, Carolina, Puerto Rico), fluorouracil (Hoffman-LaRoche, Inc, Nutley, NJ), cisplatin (Bristol Laboratories, Princeton, NJ) or hydroxyurea (Sigma Chemicals) at concentrations indicated in the figure legends. For radiation-induced cell death assays, 1 × 106 cells/mL were -irradiated using a Cobalt-60 source (dose rate: 215 cGy/min) and seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3. For long-term viability studies, cells were seeded at 1 × 105 cells/mL in either 10 µg/mL of etoposide or 1.0 µg/mL of methotrexate, washed after 3 days of continuous incubation in chemotherapy drug, and replated in IL-3 conditioned media in the absence of drug. Cell viability was measured using trypan blue exclusion. Statistical analysis was performed using STATISTICA software (Stats Soft, Tulsa, OK).
| |
RESULTS |
Bcl-XL and Bcl-2 provide similar protection from apoptosis induced by the M-phase specific vinca alkaloids, vincristine, and vinblastine.
The IL-3-dependent murine lymphoid cell line, FL5.12, was transfected with human Flag-bcl-XL or Flag-bcl-2 and individual clones were isolated by limiting dilution. Multiple FL5.12 clones expressing similar levels of Flag-Bcl-XL and Flag-Bcl-2 were identified by immunoblot and FACScan analysis using the anti-Flag MoAb. Three representative clones of each, Flag-Bcl-XL and Flag-Bcl-2, with nearly identical levels of Flag expression as determined by immunoblotting with densitometric measurements and flow cytometric analysis were selected for further study (Fig 1A and B). Flow cytometric analysis also confirmed that the selected FL5.12 clones expressed Flag-Bcl-XL and Flag-Bcl-2 uniformly in all cells (Fig 1B).
View larger version (23K):
[in this window]
[in a new window]
View larger version (19K):
[in this window]
[in a new window]
| Fig 1.
Protein expression analysis of Flag-Bcl-2 and Flag-Bcl-XL in FL5.12 clones. (A) Immunoblot analysis of FL5.12 clones. Cell lysates from FL5.12 clones expressing Flag-Bcl-XL or Flag-Bcl-2 were electrophoresed through 12.5% SDS-polyacrylamide gels, transferred to nitrocellulose and incubated with anti-Flag MoAb (1 µg/mL). Relative ratios of Flag:-tubulin protein expression determined by densitometric measurements following immunoblot analysis with anti--tubulin MoAb (clone TUB 2.1). Note that the Neo control does not contain Flag-Bcl-2 or Flag-Bcl-XL. The reaction was developed by enhanced chemiluminescence. (B) Fluorescence histograms of FL5.12 clones. Cell clones expressing Flag-Bcl-XL or Flag-Bcl-2 were analyzed for Flag-epitope expression by flow cytometry. Cells were stained with anti-Flag MoAb (1:50 dilution) and counter-stained with fluorescein isothiocyanate-conjugated Fc-specific antimouse IgG (1:50 dilution). Controls are FL5.12 clones expressing Flag-Bcl-XL (clone 14) or Flag-Bcl-2 (clone 1) stained with isotype-matched control IgG1 MoAb and counter-stained as above.
|
|
Vincristine and vinblastine, two inhibitors of tubulin polymerization, are widely used for the treatment of acute leukemias, Hodgkin's disease, non-Hodgkin's lymphomas, and neuroblastomas as well as in the treatment of many solid tumors.16 To evaluate the ability of Bcl-XL and Bcl-2 to protect cells from vincristine-induced apoptosis, we performed dose-response experiments using two representative cell clones that express similar levels of Flag-Bcl-XL and Flag-Bcl-2. At 72 hours of treatment, Bcl-XL and Bcl-2 conferred similar protection against vincristine induced apoptosis (Fig 2A). Time-course experiments using multiple Flag-Bcl-XL and Flag-Bcl-2 clones confirmed that Bcl-XL and Bcl-2 were able to confer similar protection against vincristine-induced cell death (Fig 2B). In addition, analysis of the same FL5.12 clones showed that Bcl-XL and Bcl-2 conferred a similar level of protection against vinblastine in dose-response as well as time-course experiments (Fig 2C and D). We conclude that Bcl-XL and Bcl-2 provide similar protection from apoptosis induced by the M-phase specific vinca alkaloids, vincristine, and vinblastine.
View larger version (17K):
[in this window]
[in a new window]
View larger version (17K):
[in this window]
[in a new window]
| Fig 2.
Viability of FL5.12 clones expressing Flag-Bcl-2 or Flag-Bcl-XL after vinca alkaloid treatment. (A) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of vincristine. Cells were lysed at 72 hours in a hypotonic buffer containing propidium iodide (PI) (0.01 mg/mL) and the percent of nuclei with fragmented DNA was determined by flow cytometric analysis. Viability (percent of cells with nonapoptotic nuclei) is shown as the mean ± SD of triplicate cultures. No statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each concentration of drug (P < .05, Student's t-test). The graph shown is representative of at least two separate experiments. (B) Cell viability was determined as above at each time point following continuous incubation in media containing IL-3 and 10 µg/mL of vincristine. Cells were seeded at 1 × 105 cells/mL in triplicate wells and lysed in a hypotonic buffer containing propidium iodide (0.01 mg/mL). Viability (percent of cells with nonapoptotic nuclei) is shown as the mean ± SD of triplicate cultures. No statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each time point (P < .05, Student's t-test). The graph shown is representative of at least two separate experiments. (C) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of vinblastine. Cells were lysed at 72 hours in a hypotonic buffer containing propidium iodide (0.01 mg/mL) and the percent of nuclei with fragmented DNA was determined by flow cytometric analysis. Viability (percent of cells with nonapoptotic nuclei) is shown as the mean ± SD of triplicate cultures. No statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each concentration of drug (P < .05, Student's t-test). The graph shown is representative of at least two separate experiments. (D) Cell viability was determined as above at each time point following continuous incubation in media containing IL-3 and 10 µg/mL of vinblastine. Cells were seeded at 1 × 105 cells/mL in triplicate wells and lysed in a hypotonic buffer containing propidium iodide (0.01 mg/mL). Viability (percent of cells with nonapoptotic nuclei) is shown as the mean ± SD of triplicate cultures. No statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each time point (P < .05, Student's t-test). The graph shown is representative of at least two separate experiments. The percentage of apoptotic nuclei was determined at different time points in triplicate cultures by nuclear PI staining followed by flow cytometric analysis. In this assay, the nuclei of apoptotic cells exhibit a sub-G0 profile characteristic of DNA fragmentation. Percentage of nonapoptotic nuclei is expressed as viability. Analysis was performed using Lysis II software (Becton Dickinson, San Jose, CA) on a FACScan flow cytometer. Results were based on the analysis of at least 5 × 104 events from each triplicate culture.
|
|
Bcl-XL and Bcl-2 provide differential protection from apoptosis induced by the M-phase specific epipodophyllotoxins, etoposide, and teniposide.
To determine if protection from chemotherapy-induced cell death provided by Bcl-XL and Bcl-2 was related to the cellular target or the cell-cycle activity of the chemotherapy drug, we performed experiments using etoposide (VP-16), which is an inhibitor of topoisomerase II and like vincristine and vinblastine, M-phase specific.17 As seen in Fig 3A, a dose-response experiment showed that Bcl-XL was better able to protect FL5.12 cells from VP-16-induced cell death than Bcl-2. Time-course experiments using several clones confirmed that Bcl-XL could protect cells significantly better than Bcl-2 from etoposide-induced apoptosis (Fig 3B). In addition, similar experiments using another topoisomerase II inhibitor, teniposide, confirmed that Bcl-XL could afford better protection than Bcl-2 due to epipodophyllotoxin-induced cell death (Fig 3C and D). These results indicate that Bcl-XL and Bcl-2 can differentialy inhibit cell death induced by M-phase specific chemotherapy drugs dependent on cellular target of the drug rather than by its cell-cycle phase specificity.
View larger version (16K):
[in this window]
[in a new window]
View larger version (16K):
[in this window]
[in a new window]
| Fig 3.
Viability of FL5.12 clones expressing Flag-Bcl-2 or Flag-Bcl-XL after epipodophyllotoxin treatment. (A) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of etoposide. Cells were lysed at 72 hours and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at 10 and 100 mg/mL of drug (P < .001, Student's t-test). (B) Cell viability was determined each time point following continuous incubation in media containing IL-3 and 10 µg/mL of etoposide. Cells were seeded at 1 × 105 cells/mL in triplicate wells and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at Days 3 and 4 (P < .001, Student's t-test). (C) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of teniposide. Cells were lysed at 72 hours and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at 1, 10, and 100 µg/mL of drug (P < .001, Student's t-test). (D) Cell viability was determined as above at each time point following continuous incubation in media containing IL-3 and 10 µg/mL of teniposide. Cells were seeded at 1 × 105 cells/mL in triplicate wells and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at Days 2, 3, and 4 (P < .001, Student's t-test). Graphs shown in A, B, C, and D are the mean ± SD of triplicate cultures and representative of at least two separate experiments.
|
|
Bcl-XL provides better protection than Bcl-2 from apoptosis induced by the S-phase specific chemotherapy agents, methotrexate, fluorouracil, and hydroxyurea.
Methotrexate, fluorouracil, and hydroxyurea are S-phase specific chemotherapy agents used to treat a variety of tumors. Methotrexate inhibits the enzyme, dihydrofolate reductase that is required for thymidine synthesis18 while fluorouracil potently inhibits thymidylate synthase also resulting in a decrease in thymidine synthesis as well as incorporates into RNA inhibiting its function.19 Hydroxyurea, on the other hand, inhibits the ribonucleotide reductase system that is required for conversion of ribonucleotides to deoxyribonucleotides needed in DNA synthesis and repair.20 As seen in Fig 4A and 4B, Bcl-XL protected significantly better the cells from methotrexate-induced cell death than Bcl-2 as determined in dose-response and time-course experiments. Additional dose-response experiments showed that Bcl-XL could also afford better protection than Bcl-2 against cell death induced by fluorouracil and hydroxyurea (Fig 4C and D).
View larger version (16K):
[in this window]
[in a new window]
View larger version (14K):
[in this window]
[in a new window]
| Fig 4.
Viability of FL5.12 clones expressing Flag-Bcl-2 or Flag-Bcl-XL after treatment with S-phase specific chemotherapy drugs. (A) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of methotrexate. Cells were lysed at 72 hours and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at 0.1, 1, and 10 mg/mL of drug (P < .001, Student's t-test). (B) Cell viability was determined as above at each time point following continuous incubation in media containing IL-3 and 1.0 µg/mL of methotrexate. Cells were seeded at 1 × 105 cells/mL in triplicate wells and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at Days 3 and 4 (P < .001, Student's t-test). (C) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of fluorouracil. Cells were lysed at 72 hours and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each concentration of drug (P < .001, Student's t-test). (D) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 and increasing concentrations of hydroxyurea. Cells were lysed at 72 hours and analyzed by flow cytometry as described in Fig 2. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at 10, 100, and 1,000 µg/mL of drug (P < .001, Student's t-test). Graphs shown in A, B, C, and D are the mean ± SD of triplicate cultures and representative of at least two separate experiments.
|
|
Bcl-XL and Bcl-2 provide differential protection from apoptosis induced by the DNA damaging agents -irradiation and cisplatin.
-Irradiation and cisplatin are used clinically to treat many tumors. These agents induce apoptosis in all phases of the cell-cycle by causing nonspecific DNA damage.21 Dose-response and time-course experiments revealed that Bcl-XL and Bcl-2 provided similar protection at each dose of -irradiation (Fig 5A and B). Bcl-XL, however, conferred increased survival compared to Bcl-2 when the cells were treated with cisplatin (data not shown). Interestingly, -irradiation induces DNA strand breaks through generation of oxygen free radicals while cisplatin acts as an alkylator.21 Therefore, Bcl-XL and Bcl-2, once again, provided divergent abilities to protect against chemotherapy but similar protection against -irradiation induced cell death confirming that the differential protection provided by Bcl-XL and Bcl-2 is more dependent on the specific molecular target rather than cell-cycle phase specificity of the antitumor treatment modality.
View larger version (12K):
[in this window]
[in a new window]
| Fig 5.
Viability of FL5.12 clones expressing Flag-Bcl-2 or Flag-Bcl-XL after treatment with -irradiation. (A) Cells were seeded at 1 × 105 cells/mL in triplicate wells in media containing IL-3 following increasing doses of -irradiation. Cells were lysed at 72 hours and analyzed by flow cytometry as described in Fig 2. No statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each dose of -irradiation (P < .05, Student's t-test). (B) Cell viability was determined as above at each time point following -irradiation. Cells were seeded at 1 × 105 cells/mL in triplicate wells and analyzed by flow cytometry as described in Fig 2. No statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each time point (P < .05, Student's t-test). Graphs shown in A and B are the mean ± SD of triplicate cultures and representative of at least two separate experiments.
|
|
Bcl-XL and Bcl-2 provide differential long-term protection from etoposide and methotrexate induced cell death after removal of the chemotherapy drug.
To determine if Bcl-XL and Bcl-2 could provide long-term protection from chemotherapy-induced cell death, Fl5.12 clones expressing Flag-Bcl-XL or Flag-Bcl-2 were washed out of drug after 3 days of continuous incubation in either etoposide or methotrexate and replated in media containing IL-3. As seen in Fig 6A and B, cells expressing Bcl-XL survived longer and, thus, were better able than cells expressing Bcl-2 to repopulate following removal of the chemotherapy drug. In additional experiments, FL5.12 cells expressing Bcl-2 failed to repopulate chemotherapy-free culture media following 4 days of continuous incubation in 10 mg/mL etoposide and 5 days in 1.0 µg/mL of methotrexate. Bcl-XL expressing cells, however, were still able to repopulate chemotherapy-free culture media following 6 days of incubation in etoposide and 8 days in methotrexate (data not shown). No cell-cycle changes were noted following removal of the drug compared to untreated cells expressing Flag-Bcl-XL or Flag-Bcl-2 (data not shown).
View larger version (25K):
[in this window]
[in a new window]
| Fig 6.
Viability of FL5.12 clones expressing Flag-Bcl-2 or Flag-Bcl-XL after treatment with etoposide or methotrexate. (A) 1 × 105 cells were seeded in triplicate wells in media containing IL-3 and 10 mg/mL of etoposide. At each time point, cells were counted using trypan blue exclusion to assess viability. After 3 days of continuous incubation in etoposide, the cells were washed twice and replated in triplicate at the viable cell number for Day 3 in media containing IL-3. Arrow indicates time point at which the cells were washed and replated in drug-free media containing IL-3. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each time point after Day 1 (P < .01, Student's t-test). (B) 1 × 105 cells were seeded in triplicate wells in media containing IL-3 and 1.0 mg/mL of methotrexate. At each time point, cells were counted using trypan blue exclusion to assess viability. After 3 days of continuous incubation in methotrexate, the cells were washed twice and replated in triplicate at the viable cell number for Day 3 in media containing IL-3. Arrow indicates time point at which the cells were washed and replated in drug-free media containing IL-3. A statistical significance was found between Flag-Bcl-2 and Flag-Bcl-XL clones at each time point after Day 1 (P < .01, Student's t-test).
|
|
| |
DISCUSSION |
Susceptibility of a cell to apoptotic signals appears to be regulated in part by the relative levels and competing dimerizations between Bcl-2 family members as well as competition for other cellular factors involved in the cell death pathway.14,22-24 Many neoplastic cells express either Bcl-2 or Bcl-XL and these apoptosis-suppressing proteins as well as other Bcl-2 family members have been implicated in relative resistance and susceptibility to antitumor treatment. In this report, we assessed if similar levels of Bcl-2 and Bcl-XL expression could provide equal protection against a variety of chemotherapy agents and -irradiation. We found that Bcl-XL provided enhanced protection versus Bcl-2 upon treatment with the M-phase specific chemotherapy agents, etoposide and teniposide, the S-phase specific antitumor agents, methotrexate, fluorouracil, and hydroxyurea and the cell-cycle nonspecific agent, cisplatin. However, Bcl-2 and Bcl-XL afforded similar protection against cell death on treatment with vincristine, vinblastine, and -irradiation. Several possibilities may explain these findings. First, Bcl-XL and Bcl-2 are thought to regulate a common cell death pathway. If all of the antitumor agents shown use a final common pathway, these results suggest that other cellular factors may be required for Bcl-XL and Bcl-2 to modulate this pathway since Bcl-XL and Bcl-2 did not provide equal protection upon treatment with all of these antitumor agents. These cellular factors could differentially regulate Bcl-XL and Bcl-2. Second, apoptotic stimuli including chemotherapy agents are known to activate a family of ICE/CED-3 cysteine proteases, which are thought to serve as executioners of the death pathway.25 Bcl-2 and Bcl-XL appear to act upstream and inhibit the activation of the death cysteine proteases.26 Therefore, it is plausible that certain chemotherapy agents activate different proteases which may be differentially blocked by Bcl-XL and Bcl-2. Another possibility is that chemotherapy agents differentially modify the expression/activity of Bcl-XL and Bcl-2 or other proteins that regulate the function of these survival proteins. Although we found no substantial change in levels of Bcl-2 family members including Bcl-2, Bcl-XL, Bax, and Bad in FL5.12 cells after treatment with these chemotherapy drugs (data not shown), we cannot exclude that other Bcl-2 family members or other regulatory proteins yet to be discovered could be altered by chemotherapy agents and could differentially affect the protective ability of Bcl-XL and Bcl-2. Additionally, it is possible that certain chemotherapy agents could biochemically modify Bcl-2 or Bcl-XL. In this regard, chemotherapy agents, such as taxol and fluorouracil, have been shown to induce posttranslational modification of Bcl-2 through phosphorylation,27 which has been suggested to modulate the anti-apoptotic activity of Bcl-2.28,29 Therefore, it is possible that certain chemotherapy drugs differentially regulate phosphorylation or dephosphorylation of Bcl-2 and Bcl-XL and selectively affect their ability to inhibit apoptosis. Finally, Bcl-2 has been shown to slow entry of cells from G0 into S.30,31 The Flag-Bcl-XL and Flag-Bcl-2 expressing FL5.12 clones used in these studies, however, did not show cell-cycle differences compared to the Neo control and untransfected FL5.12 cells while continuously cycling in culture media containing IL-3 and after removal of chemotherapy drugs (data not shown).
The expression of Bcl-2 and Bcl-XL has been implicated in the resistance of tumors to therapy. Unfortunately, treatment resistance and recurrence still remain formidable obstacles to the cure of most cancers. Since chemotherapy drugs and -irradiation destroy cancer cells by activating the cell death pathway, our studies suggest that the choice of antitumor agents should take into account the levels of Bcl-XL and Bcl-2 expressed by the tumor cells. Tumor cells that escape chemotherapy-induced cell death may continue to proliferate resulting in a relapse of the cancer. The fact that Bcl-XL was better able than Bcl-2 to protect FL5.12 cells from cell death induced by certain chemotherapy drugs suggests that Bcl-XL expressing tumor cells may be more difficult to completely destroy than cancer cells expressing Bcl-2. Clinically, chemotherapy drugs are inactivated or excreted from the body. Therefore, tumor cells that express Bcl-XL may be more likely to escape initial destruction by certain chemotherapy treatments than neoplasms expressing Bcl-2 increasing the likelihood of relapse. Our studies were performed in FL5.12 progenitor B cells so it is unclear if they similarly apply to cancer cells derived from different lineages. Future studies will determine if more powerful treatment stategies can be developed based on Bcl-XL or Bcl-2 expression and their divergent abilities to protect against certain chemotherapy-induced cell deaths in different cancers.
| |
FOOTNOTES |
Submitted January 3, 1997;
accepted March 21, 1997.
Supported by Grant No. CA-64556 from the National Institutes of Health (NIH); National Research Service Award, National Institute on Aging, NIH (P.L.S.); Fellowship from the Swiss National Science Foundation (D.A.M.G.); and Research Career Development Award CA-64421 from the NIH (G.N.).
Address reprint requests to Gabriel Nuñez, MD, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
ACKNOWLEDGMENT |
The authors thank Valerie Castle, Michael Clarke, Maribel Gonzalez-Garcia, J. Rebecca Liu, and Max Wicha for their critical review of this manuscript.
| |
REFERENCES |
1.
Thompson CB:
Apoptosis in the pathogenesis and treatment of disease.
Science
267:1456,
1995[Abstract/Free Full Text]
2.
Tsujimoto Y,
Gorham J,
Cossman J,
Jaffe E,
Croce CM:
The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.
Science
229:1390,
1985[Abstract/Free Full Text]
3.
Miyashita T,
Reed JC:
Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.
Blood
81:151,
1993[Abstract/Free Full Text]
4.
Campos L,
Rouault JP,
Sabido O,
Oriol P,
Roubi N,
Vasselon C,
Archimbaud E,
Magaud JP,
Guyotat D:
High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.
Blood
81:3091,
1993[Abstract/Free Full Text]
5.
Hanada M,
Delia D,
Aiello A,
Stadtmauer E,
Reed JC:
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.
Blood
82:1820,
1993[Abstract/Free Full Text]
6.
Reed JC:
Bcl-2: prevention of apoptosis as a mechanism of drug resistance.
Hematol Oncol Clin North Am
9:451,
1995[Medline]
[Order article via Infotrieve]
7.
Minn AJ,
Rudin CM,
Boise LH,
Thompson CB:
Expression of bcl-xL can confer a multidrug resistance phenotype.
Blood
86:1903,
1995[Abstract/Free Full Text]
8.
Krajewska M,
Moss SF,
Krajewski S,
Song K,
Holt PR,
Reed JC:
Elevated expression of Bcl-X and reduced Bak expression in primary colorectal adenocarcinomas.
Cancer Res
56:2422,
1996[Abstract/Free Full Text]
9.
Bargou RC,
Daniel PT,
Mapara MY,
Bommert K,
Wagener C,
Kallinich B,
Royer HD,
Dorken B:
Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-alpha expression in tumor cells correlates with resistance towards apoptosis.
Int J Cancer
60:854,
1995[Medline]
[Order article via Infotrieve]
10.
Chao DT,
Linette GP,
Boise LH,
White LS,
Thompson CB,
Korsmeyer SJ:
Bcl-XL and Bcl-2 repress a common pathway of cell death.
J Exp Med
182:821,
1995[Abstract/Free Full Text]
11.
Gottschalk AR,
Boise LH,
Thompson CB,
Quintans J:
Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2.
Proc Natl Acad Sci USA
91:7350,
1994[Abstract/Free Full Text]
12.
Nunez G,
London L,
Hockenbery D,
Alexander M,
McKearn JP,
Korsmeyer SJ:
Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.
J Immunol
144:3602,
1990[Abstract]
13.
Merino R,
Grillot DA,
Simonian PL,
Muthukkumar S,
Fanslow WC,
Bondada S,
Nunez G:
Modulation of anti-IgM-induced B cell apoptosis by Bcl-xL and CD40 in WEHI-231 cells. Dissociation from cell-cycle arrest and dependence on the avidity of the antibody-IgM receptor interaction.
J Immunol
155:3830,
1995[Abstract]
14.
Simonian PL,
Grillot DAM,
Merino R,
Nunez G:
Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL.
J Biol Chem
271:22764,
1996[Abstract/Free Full Text]
15.
Simonian PL,
Grillot DAM,
Andrews DW,
Leber B,
Nunez G:
Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death.
J Biol Chem
271:32073,
1996[Abstract/Free Full Text]
16. Rowinsky EK, Donehower RC: Antimicrotubule agents, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 264
17. Pommier YG, Fesen MR, Goldwasser F: Topoisomerase II inhibitors: The epipodophyllotoxins, m-AMSA, and the ellipticine derivatives, in Chabner BA Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 437
18. Chu E, Allegra CJ: Antifolates, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 109
19. Grem JL: 5-Fluoropyrimidines, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 150
20. Donehower RC: Hydroxyurea, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 255
21. Reed E, Dabholkar M, Chabner BA: Platinum analogues, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1996, p 361
22.
Boise LH,
Gonzalez-Garcia M,
Postema CE,
Ding L,
Lindsten T,
Turka LA,
Mao X,
Nunez G,
Thompson CB:
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.
Cell
74:597,
1993[Medline]
[Order article via Infotrieve]
23.
Cheng EHY,
Levine B,
Boise LH,
Thompson CB,
Hardwick JM:
Bax-independent inhibition of apoptosis by Bcl-XL.
Nature
379:554,
1996[Medline]
[Order article via Infotrieve]
24.
Boyd JM,
Gallo GJ,
Elangovan B,
Houghton AB,
Malstrom S,
Avery BJ,
Ebb RG,
Subramanian T,
Chittenden T,
Lutz RJ,
Chinnadurai G:
Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins.
Oncogene
11:1921,
1995[Medline]
[Order article via Infotrieve]
25.
Datta R,
Banach D,
Kojima H,
Talanian RV,
Alnemri ES,
Wong WW,
Kufe DW:
Activation of the CPP32 protease in apoptosis induced by 1-b-D-arabinofuranosylcytosine and other DNA-damaging agents.
Blood
88:1936,
1996[Abstract/Free Full Text]
26.
Chinnaiyan AM,
Orth K,
O'Rourke K,
Duan H,
Poirier GG,
Dixit VM:
Molecular ordering of the cell death pathway.
J Biol Chem
271:4573,
1996[Abstract/Free Full Text]
27.
Halder S,
Jena N,
Croce CM:
Antiapoptosis potential of bcl-2 oncogene by dephosphorylation.
Biochem Cell Biol
72:455,
1994[Medline]
[Order article via Infotrieve]
28.
Halder S,
Jena N,
Croce CM:
Inactivation of Bcl-2 by phosphorylation.
Proc Natl Acad Sci USA
92:4507,
1995[Abstract/Free Full Text]
29.
May WS,
Tyler PG,
Ito T,
Armstrong DK,
Qatsha KA,
Davidson NE:
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl-2a in association with suppression of apoptosis.
J Biol Chem
269:26865,
1994[Abstract/Free Full Text]
30.
O'Reilly LA,
Huang DCS,
Strasser A:
The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.
EMBO J
15:6979,
1996[Medline]
[Order article via Infotrieve]
31.
Linette GP,
Li Y,
Roth K,
Korsmeyer SJ:
Cross talk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation.
Proc Natl Acad Sci USA
93:9545,
1996[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. L. Hurwitz, F. McCoy, P. Scullin, and D. A. Fennell
New Advances in the Second-Line Treatment of Small Cell Lung Cancer
Oncologist,
October 1, 2009;
14(10):
986 - 994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dornan, F. Bennett, Y. Chen, M. Dennis, D. Eaton, K. Elkins, D. French, M. A. T. Go, A. Jack, J. R. Junutula, et al.
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
Blood,
September 24, 2009;
114(13):
2721 - 2729.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Pandey, B. Sung, K. S. Ahn, and B. B. Aggarwal
Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1
Mol. Pharmacol.,
March 1, 2009;
75(3):
525 - 533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-S. Shin, H.-N. Kim, K. D. Shin, Y. J. Yoon, S.-J. Kim, D. C. Han, and B.-M. Kwon
Cryptotanshinone Inhibits Constitutive Signal Transducer and Activator of Transcription 3 Function through Blocking the Dimerization in DU145 Prostate Cancer Cells
Cancer Res.,
January 1, 2009;
69(1):
193 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Meng, W. Tang, Y. Dai, X. Wu, M. Liu, Q. Ji, M. Ji, K. Pienta, T. Lawrence, and L. Xu
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
Mol. Cancer Ther.,
July 1, 2008;
7(7):
2192 - 2202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Pathak, M. Bhutani, A. S. Nair, K. S. Ahn, A. Chakraborty, H. Kadara, S. Guha, G. Sethi, and B. B. Aggarwal
Ursolic Acid Inhibits STAT3 Activation Pathway Leading to Suppression of Proliferation and Chemosensitization of Human Multiple Myeloma Cells
Mol. Cancer Res.,
September 1, 2007;
5(9):
943 - 955.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bhutani, A. K. Pathak, A. S. Nair, A. B. Kunnumakkara, S. Guha, G. Sethi, and B. B. Aggarwal
Capsaicin Is a Novel Blocker of Constitutive and Interleukin-6-Inducible STAT3 Activation
Clin. Cancer Res.,
May 15, 2007;
13(10):
3024 - 3032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bhardwaj, G. Sethi, S. Vadhan-Raj,, C. Bueso-Ramos, Y. Takada, U. Gaur, A. S. Nair, S. Shishodia, and B. B. Aggarwal
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-{kappa}B-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells
Blood,
March 15, 2007;
109(6):
2293 - 2302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke
Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL
Mol. Cancer Ther.,
December 1, 2006;
5(12):
3170 - 3180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Shoemaker, A. Oleksijew, J. Bauch, B. A. Belli, T. Borre, M. Bruncko, T. Deckwirth, D. J. Frost, K. Jarvis, M. K. Joseph, et al.
A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo.
Cancer Res.,
September 1, 2006;
66(17):
8731 - 8739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Yamanaka, P. Rocchi, H. Miyake, L. Fazli, B. Vessella, U. Zangemeister-Wittke, and M. E. Gleave
A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells
Mol. Cancer Ther.,
November 1, 2005;
4(11):
1689 - 1698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Bharti, S. Shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal
Nuclear factor-{kappa}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
Blood,
April 15, 2004;
103(8):
3175 - 3184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-L. Zhao, M. E. Daneshpouy, N. Mounier, J. Briere, C. Leboeuf, L.-F. Plassa, E. Turpin, J.-M. Cayuela, J.-C. Ameisen, C. Gisselbrecht, et al.
Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma
Blood,
January 15, 2004;
103(2):
695 - 697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. R. Fantin and P. Leder
F16, a Mitochondriotoxic Compound, Triggers Apoptosis or Necrosis Depending on the Genetic Background of the Target Carcinoma Cell
Cancer Res.,
January 1, 2004;
64(1):
329 - 336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Molto, P. Rayman, E. Paszkiewicz-Kozik, M. Thornton, L. Reese, J. C. Thomas, T. Das, D. Kudo, R. Bukowski, J. Finke, et al.
The Bcl-2 Transgene Protects T Cells from Renal Cell Carcinoma-mediated Apoptosis
Clin. Cancer Res.,
September 15, 2003;
9(11):
4060 - 4068.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yacoub, C. Mitchell, A. Lister, I. V. Lebedeva, D. Sarkar, Z.-Z. Su, C. Sigmon, R. McKinstry, V. Ramakrishnan, L. Qiao, et al.
Melanoma Differentiation-associated 7 (Interleukin 24) Inhibits Growth and Enhances Radiosensitivity of Glioma Cells in Vitro and in Vivo
Clin. Cancer Res.,
August 1, 2003;
9(9):
3272 - 3281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Oleinik and S. A. Krupenko
Ectopic Expression of 10-Formyltetrahydrofolate Dehydrogenase in A549 Cells Induces G1 Cell Cycle Arrest and Apoptosis
Mol. Cancer Res.,
June 1, 2003;
1(8):
577 - 588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Hafid-Medheb, Y. Augery-Bourget, M.-N. Minatchy, N. Hanania, and J. Robert-Lezenes
Bcl-XL is required for heme synthesis during the chemical induction of erythroid differentiation of murine erythroleukemia cells independently of its antiapoptotic function
Blood,
April 1, 2003;
101(7):
2575 - 2583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Zhang, T. Zhu, Y. Chen, H. C. Mertani, K.-O. Lee, and P. E. Lobie
Human Growth Hormone-regulated HOXA1 Is a Human Mammary Epithelial Oncogene
J. Biol. Chem.,
February 21, 2003;
278(9):
7580 - 7590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Tortora, R. Caputo, V. Damiano, R. Caputo, T. Troiani, B. M. Veneziani, S. De Placido, A. R. Bianco, U. Zangemeister-Wittke, and F. Ciardiello
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
Clin. Cancer Res.,
February 1, 2003;
9(2):
866 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Alas and B. Bonavida
Inhibition of Constitutive STAT3 Activity Sensitizes Resistant Non-Hodgkin's Lymphoma and Multiple Myeloma to Chemotherapeutic Drug-mediated Apoptosis
Clin. Cancer Res.,
January 1, 2003;
9(1):
316 - 326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, S. Wang, Y. Dai, and S. Grant
Bryostatin 1 Increases 1-beta -D-Arabinofuranosylcytosine-Induced Cytochrome c Release and Apoptosis in Human Leukemia Cells Ectopically Expressing Bcl-xL
J. Pharmacol. Exp. Ther.,
May 1, 2002;
301(2):
568 - 577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Walzer, C. Arpin, L. Beloeil, and J. Marvel
Differential In Vivo Persistence of Two Subsets of Memory Phenotype CD8 T Cells Defined by CD44 and CD122 Expression Levels
J. Immunol.,
March 15, 2002;
168(6):
2704 - 2711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Oshiro, T. H. Landowski, R. Catlett-Falcone, L. A. Hazlehurst, M. Huang, R. Jove, and W. S. Dalton
Inhibition of JAK Kinase Activity Enhances Fas-mediated Apoptosis but Reduces Cytotoxic Activity of Topoisomerase II Inhibitors in U266 Myeloma Cells
Clin. Cancer Res.,
December 1, 2001;
7(12):
4262 - 4271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ekhterae, O. Platoshyn, S. Krick, Y. Yu, S. S. McDaniel, and J. X.-J. Yuan
Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells
Am J Physiol Cell Physiol,
July 1, 2001;
281(1):
C157 - C165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Gautschi, S. Tschopp, R. A. Olie, S. H. Leech, A. P. Simoes-Wust, A. Ziegler, B. Baumann, B. Odermatt, J. Hall, R. A. Stahel, et al.
Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins
J Natl Cancer Inst,
March 21, 2001;
93(6):
463 - 471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Lebedeva, R. Rando, J. Ojwang, P. Cossum, and C. A. Stein
Bcl-xL in Prostate Cancer Cells: Effects of Overexpression and Down-Regulation on Chemosensitivity
Cancer Res.,
November 1, 2000;
60(21):
6052 - 6060.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. A. Amundson, T. G. Myers, D. Scudiero, S. Kitada, J. C. Reed, and A. J. Fornace Jr.
An Informatics Approach Identifying Markers of Chemosensitivity in Human Cancer Cell Lines
Cancer Res.,
November 1, 2000;
60(21):
6101 - 6110.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Gao and Q. P. Dou
G1 Phase-Dependent Expression of Bcl-2 mRNA and Protein Correlates with Chemoresistance of Human Cancer Cells
Mol. Pharmacol.,
November 1, 2000;
58(5):
1001 - 1010.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Nicot, R. Mahieux, S. Takemoto, and G. Franchini
Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples
Blood,
July 1, 2000;
96(1):
275 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Walczak, A. Bouchon, H. Stahl, and P. H. Krammer
Tumor Necrosis Factor-related Apoptosis-inducing Ligand Retains Its Apoptosis-inducing Capacity on Bcl-2- or Bcl-xL-overexpressing Chemotherapy-resistant Tumor Cells
Cancer Res.,
June 1, 2000;
60(11):
3051 - 3057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Zangemeister-Wittke, S. H. Leech, R. A. Olie, A. P. Simões-Wüst, O. Gautschi, G. H. Luedke, F. Natt, R. Häner, P. Martin, J. Hall, et al.
A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells
Clin. Cancer Res.,
June 1, 2000;
6(6):
2547 - 2555.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Ekhterae, Z. Lin, M. S. Lundberg, M. T. Crow, F. C. Brosius III, and G. Nunez
ARC Inhibits Cytochrome c Release From Mitochondria and Protects Against Hypoxia-Induced Apoptosis in Heart-Derived H9c2 Cells
Circ. Res.,
December 3, 1999;
85
(12):
e70 - e77.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Liu, C. Page, D. R. Beidler, M. S. Wicha, and G. Nunez
Overexpression of Bcl-xL Promotes Chemotherapy Resistance of Mammary Tumors in a Syngeneic Mouse Model
Am. J. Pathol.,
December 1, 1999;
155(6):
1861 - 1867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bairey, Y. Zimra, M. Shaklai, E. Okon, and E. Rabizadeh
Bcl-2, Bcl-X, Bax, and Bak Expression in Short- and Long-Lived Patients with Diffuse Large B-Cell Lymphomas
Clin. Cancer Res.,
October 1, 1999;
5(10):
2860 - 2866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Shinoura, Y. Yoshida, M. Nishimura, Y. Muramatsu, A. Asai, T. Kirino, and H. Hamada
Expression Level of Bcl-2 Determines Anti- or Proapoptotic Function
Cancer Res.,
August 1, 1999;
59(16):
4119 - 4128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. T. Daniel, K.-T. Pun, S. Ritschel, I. Sturm, J. Holler, B. Dorken, and R. Brown
Expression of the Death Gene Bik/Nbk Promotes Sensitivity to Drug-Induced Apoptosis in Corticosteroid-Resistant T-Cell Lymphoma and Prevents Tumor Growth in Severe Combined Immunodeficient Mice
Blood,
August 1, 1999;
94(3):
1100 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Terui, M. Ikeda, H. Tomizuka, T. Kasahara, T. Ohtsuki, M. Uwai, M. Mori, T. Itoh, M. Tanaka, M. Yamada, et al.
Activated Endothelial Cells Induce Apoptosis in Leukemic Cells by Endothelial Interleukin-8
Blood,
October 15, 1998;
92(8):
2672 - 2680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Derfuss, H. Fickenscher, M. S. Kraft, G. Henning, D. Lengenfelder, B. Fleckenstein, and E. Meinl
Antiapoptotic Activity of the Herpesvirus Saimiri-Encoded Bcl-2 Homolog: Stabilization of Mitochondria and Inhibition of Caspase-3-Like Activity
J. Virol.,
July 1, 1998;
72(7):
5897 - 5904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract